Intellia’s CRISPR therapy lonvoguran ziclumeran (lonvo-z) drew further market momentum after additional Phase 3 readouts in hereditary angioedema. The company said the HAELO trial met the primary endpoint and, in newly reported secondary outcomes, also showed improvements including reduced monthly attacks requiring on-demand treatment and fewer moderate-to-severe episodes. Intellia also reported quality-of-life gains on the AE-QoL total score by week 28 compared with placebo. The results were presented at the EAACI annual congress and published in The New England Journal of Medicine. The company is continuing its rolling Biologics License Application submission begun in April, aiming to complete the BLA by year-end and potentially launch in the first half of 2027 if FDA approval is secured. Investors will now focus on the totality of clinical performance and the label breadth question—particularly around durability, prophylaxis discontinuation rates, and safety across the full clinical dataset.